HIVE
HIVE Digital Technologies Ltd.
There isn't enough reported data to score HIVE yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
HIVE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| N/A | |
| N/A |
HIVE's revenue is currently healthy, but its profitability is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIVE.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
HIVE PE Valuation
HIVE has no meaningful PE right now: it lost money over the past year.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
HIVE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect HIVE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
HIVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.60 | -1433% |
| Q2 2026 | -$1.38 | -1162% |
| Q1 2026 | -$0.66 | -$0.44 |
| Q4 2025 | -$0.27 | -154% |
| Q3 2025 | $0.12 | -71% |
| Q2 2025 | $0.13 | -28% |
| Q1 2025 | -$0.22 | -238% |
| Q4 2024 | $0.50 | +$0.98 |
HIVE has swung to a loss: it lost $1.60 per share over the past year, after a profit the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over HIVE on earnings quality, reporting a profit while its opponent remains loss making.
HIVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $84.9M | -2.7% |
| Q2 2026 | $79.1M | +73% |
| Q1 2026 | $71.8M | +130% |
| Q4 2025 | $93.1M | +219% |
| Q3 2025 | $87.3M | +285% |
| Q2 2025 | $45.6M | +41% |
| Q1 2025 | $31.2M | -16% |
| Q4 2024 | $29.2M | -6.5% |
HIVE's revenue is growing: $85M last quarter, down 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -227% | -232 points |
| Q4 2025 | 18% | +25 points |
| Q3 2025 | -11% | +9.1 points |
| Q2 2025 | 78% | +132 points |
| Q1 2025 | 5.2% | -84 points |
| Q4 2024 | -7% | -30 points |
| Q3 2024 | -20% | -6.7 points |
| Q2 2024 | -54% | -68 points |
HIVE's operating margin was −227% last quarter, down 232 points from the same quarter a year ago, near the bottom of its range since 2019.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
HIVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $858K | +$49.1M |
| Q2 2026 | -$10.7M | +$26.4M |
| Q1 2026 | -$21.8M | +$7.8M |
| Q4 2025 | -$9M | +$80.9M |
| Q3 2025 | -$48.2M | -$26.2M |
| Q2 2025 | -$37.1M | -$19.4M |
| Q1 2025 | -$29.5M | +$8.3M |
| Q4 2024 | -$89.9M | -$63.8M |
HIVE has the edge over MS on cash flow, with more consistent year-over-year improvement.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
HIVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.9% | +7.8M shares |
| 1 year | +20% | +45.9M shares |
| 3 years | +222% | +189M shares |
| 5 years | +242% | +194M shares |
| Available history | +319% | +209M shares |
HIVE has 274M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over HIVE on shareholder dilution, with a more favorable share count trend.
HIVE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.0x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.3x | Very low |
| Q2 2024 | 0.0x | Very low |
HIVE's net debt is about 1.8 years of its operating earnings (EBITDA), down from 4.1 years a year ago. Net leverage isn't a meaningful measure for financial services companies like HIVE.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
HIVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 6.1 | Oversold |
HIVE's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
HIVE PE vs Financial Services Sector
| Metric | HIVE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
HIVE has no meaningful PE right now: it lost money over the past year.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
HIVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 26% below |
| 20 week MA | $2.70 | 39% below |
| 50 week MA | $2.79 | 41% below |
| 100 week MA | $2.78 | 41% below |
| 200 week MA | $3.12 | 47% below |
HIVE is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over HIVE on trend strength, trading above more of its moving averages.
HIVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $8.30 | +1975% |
| 2021 | $8.30 | $15.3 | +84% |
| 2022 | $15.3 | $1.59 | -90% |
| 2023 | $1.59 | $4.53 | +185% |
| 2024 | $4.53 | $2.97 | -34% |
| 2025 | $2.97 | $2.72 | -8.4% |
| 2026 YTD | $2.72 | $1.65 | -39% |
HIVE's yearly returns have swung widely, from +1975% in 2020 to −90% in 2022. It's down 39% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over HIVE on returns for 2026, with the stronger performance.